Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2021 Mar 12:12:630550.
doi: 10.3389/fendo.2021.630550. eCollection 2021.

Low Prognosis by the POSEIDON Criteria in Women Undergoing Assisted Reproductive Technology: A Multicenter and Multinational Prevalence Study of Over 13,000 Patients

Sandro C Esteves  1 , Hakan Yarali  2   3 , Lan N Vuong  4   5   6 , José F Carvalho  7 , İrem Y Özbek  2 , Mehtap Polat  2 , Ho L Le  4   5 , Toan D Pham  4   5 , Tuong M Ho  4   5
Affiliations
Multicenter Study

Low Prognosis by the POSEIDON Criteria in Women Undergoing Assisted Reproductive Technology: A Multicenter and Multinational Prevalence Study of Over 13,000 Patients

Sandro C Esteves et al. Front Endocrinol (Lausanne). .

Abstract

Objective: To estimate the prevalence of low-prognosis patients according to the POSEIDON criteria using real-world data.

Design: Multicenter population-based cohort study.

Settings: Fertility clinics in Brazil, Turkey, and Vietnam.

Patients: Infertile women undergoing assisted reproductive technology using standard ovarian stimulation with exogenous gonadotropins.

Interventions: None.

Main outcome measures: Per-period prevalence rates of POSEIDON patients (overall, stratified by POSEIDON groups and by study center) and the effect of covariates on the probability that a patient be classified as "POSEIDON".

Results: A total of 13,146 patients were included. POSEIDON patients represented 43.0% (95% confidence interval [CI] 42.0-43.7) of the studied population, and the prevalence rates varied across study centers (range: 38.6-55.7%). The overall prevalence rates by POSEIDON groups were 44.2% (group 1; 95% CI 42.6-45.9), 36.1% (group 2; 95% CI 34.6-37.7), 5.2% (group 3; 95% CI 4.5-6.0), and 14.4% (group 4; 95% CI: 13.3-15.6). In general, POSEIDON patients were older, had a higher body mass index (BMI), lower ovarian reserve markers, and a higher frequency of female factor as the primary treatment indication than non-POSEIDON patients. The former required larger doses of gonadotropin for ovarian stimulation, despite achieving a 2.5 times lower number of retrieved oocytes than non-POSEIDON patients. Logistic regression analyses revealed that female age, BMI, ovarian reserve, and a female infertility factor were relevant predictors of the POSEIDON condition.

Conclusions: The estimated prevalence of POSEIDON patients in the general population undergoing ART is significant. These patients differ in clinical characteristics compared with non-POSEIDON patients. The POSEIDON condition is associated with female age, ovarian reserve, BMI, and female infertility. Efforts in terms of diagnosis, counseling, and treatment are needed to reduce the prevalence of low-prognosis patients.

Keywords: POSEIDON criteria; assisted reproductive technology; infertility; prevalence study; real-world evidence.

PubMed Disclaimer

Conflict of interest statement

SE is a co-founder of the POSEIDON group and declares receipt of unrestricted research grants from Merck and lecture fees from Merck and Med.E.A. HY declares receipt of payment for lectures from Merck and Ferring. LV receives speaker fees and conferences from Merck, Merck Sharp and Dohme (MSD) and Ferring and research grants from MSD and Ferring. TH received speaker fees and conferences from Merck, MSD and Ferring. JC is an employee of Statistika Consulting. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Flow diagram showing total patient breakdown.
See this image and copyright information in PMC

References

    1. Alviggi C, Andersen CY, Buehler K, Conforti A, De Placido G, Esteves SC, et al. A new more detailed stratification of low responders to ovarian stimulation: from a poor ovarian response to a low prognosis concept. Fertil Steril (2016) 105:1452. 10.1016/j.fertnstert.2016.02.005 - DOI - PubMed
    1. Humaidan P, Alviggi C, Fischer R, Esteves SC. The novel POSEIDON stratification of ‘Low prognosis patients in Assisted Reproductive Technology’ and its proposed marker of successful outcome. F1000Res (2016) 5:2911. 10.12688/f1000research.10382.1 - DOI - PMC - PubMed
    1. Esteves SC, Alviggi C, Humaidan P, Fischer R, Andersen CY, Conforti A, et al. The POSEIDON criteria and its measure of success through the eyes of clinicians and embryologists. Front Endocrinol (Lausanne) (2019) 10:814. 10.3389/fendo.2019.00814 - DOI - PMC - PubMed
    1. Li Y, Li X, Yang X, Cai S, Lu G, Lin G, et al. Cumulative live birth rates in low prognosis patients according to the POSEIDON criteria: an analysis of 26,697 cycles of in vitro fertilization/intracytoplasmic sperm injection. Front Endocrinol (Lausanne) (2019) 10:642. 10.3389/fendo.2019.00642 - DOI - PMC - PubMed
    1. Shi W, Zhou H, Tian L, Zhao Z, Zhang W, Shi J. Cumulative live birth rates of good and low prognosis patients according to POSEIDON criteria: a single center analysis of 18,455 treatment cycles. Front Endocrinol (Lausanne) (2019) 10:409. 10.3389/fendo.2019.00409 - DOI - PMC - PubMed

Publication types